Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study

Cindy X. Cai, Akihiko Nishimura, Mary G. Bowring, Erik Westlund, Diep Tran, Jia H. Ng, Paul Nagy, Michael Cook, Jody Ann McLeggon, Scott L. DuVall, Michael E. Matheny, Asieh Golozar, Anna Ostropolets, Evan Minty, Priya Desai, Fan Bu, Brian Toy, Michelle Hribar, Thomas Falconer, Linying ZhangLaurence Lawrence-Archer, Michael V. Boland, Kerry Goetz, Nathan Hall, Azza Shoaibi, Jenna Reps, Anthony G. Sena, Clair Blacketer, Joel Swerdel, Kenar D. Jhaveri, Edward Lee, Zachary Gilbert, Scott L. Zeger, Deidra C. Crews, Marc A. Suchard, George Hripcsak, Patrick B. Ryan

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science